Ignite Creation Date:
2025-12-24 @ 10:09 PM
Ignite Modification Date:
2026-03-11 @ 12:56 AM
Study NCT ID:
NCT02557035
Status:
COMPLETED
Last Update Posted:
2018-06-20
First Post:
2015-09-21
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D014839', 'term': 'Vomiting'}], 'ancestors': [{'id': 'D012817', 'term': 'Signs and Symptoms, Digestive'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077924', 'term': 'Palonosetron'}, {'id': 'D003907', 'term': 'Dexamethasone'}], 'ancestors': [{'id': 'D011812', 'term': 'Quinuclidines'}, {'id': 'D006572', 'term': 'Heterocyclic Compounds, Bridged-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D007546', 'term': 'Isoquinolines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D011246', 'term': 'Pregnadienetriols'}, {'id': 'D011245', 'term': 'Pregnadienes'}, {'id': 'D011278', 'term': 'Pregnanes'}, {'id': 'D013256', 'term': 'Steroids'}, {'id': 'D000072473', 'term': 'Fused-Ring Compounds'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D013259', 'term': 'Steroids, Fluorinated'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'daniel.voisin@helsinn.com', 'phone': '+41 91 985 2121', 'title': 'Daniel Voisin', 'organization': 'Helsinn Healthcare SA'}, 'certainAgreement': {'restrictionType': 'LTE60', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': '7 months', 'eventGroups': [{'id': 'EG000', 'title': 'I.V. Palonosetron Infusion Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone', 'otherNumAtRisk': 225, 'deathsNumAtRisk': 225, 'otherNumAffected': 14, 'seriousNumAtRisk': 225, 'deathsNumAffected': 1, 'seriousNumAffected': 15}, {'id': 'EG001', 'title': 'I.V. Palonosetron Bolus Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone', 'otherNumAtRisk': 215, 'deathsNumAtRisk': 215, 'otherNumAffected': 22, 'seriousNumAtRisk': 215, 'deathsNumAffected': 0, 'seriousNumAffected': 12}], 'otherEvents': [{'term': 'Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 11}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 11}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'seriousEvents': [{'term': 'Leukopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 3}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Thrombocytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Atrial fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Atrial flutter', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Cardiac arrest', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Cardio-respiratory arrest', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Abdominal pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Mesenteric vein thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Death', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Disease progression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Pain', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Sepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Brain contusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Subdural haematoma', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Blood creatinine increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Blood urea increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'ECG signs of myocardial infarction', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Dehydration', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Hypokalaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Hyponatraemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Malignant neoplasm progression', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Epilepsy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Transient ischaemic attack', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Dyspnoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Pulmonary embolism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Respiratory failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Angioedema', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Dermatitis allergic', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 1}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Hypotension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 225, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 215, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Acute Phase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '225', 'groupId': 'OG000'}, {'value': '215', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'I.V. Palonosetron Infusion Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}, {'id': 'OG001', 'title': 'I.V. Palonosetron Bolus Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}], 'classes': [{'categories': [{'measurements': [{'value': '186', 'groupId': 'OG000'}, {'value': '186', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '0-24 hours', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Delayed Phase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '225', 'groupId': 'OG000'}, {'value': '215', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'I.V. Palonosetron Infusion Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}, {'id': 'OG001', 'title': 'I.V. Palonosetron Bolus Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}], 'classes': [{'categories': [{'measurements': [{'value': '170', 'groupId': 'OG000'}, {'value': '165', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '>24-120 hours', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Overall Phase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '225', 'groupId': 'OG000'}, {'value': '215', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'I.V. Palonosetron Infusion Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}, {'id': 'OG001', 'title': 'I.V. Palonosetron Bolus Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}], 'classes': [{'categories': [{'measurements': [{'value': '150', 'groupId': 'OG000'}, {'value': '156', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '0-120 hours', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Percentage of Patients With no Emetic Episodes in the Acute Phase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '225', 'groupId': 'OG000'}, {'value': '215', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'I.V. Palonosetron Infusion Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}, {'id': 'OG001', 'title': 'I.V. Palonosetron Bolus Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}], 'classes': [{'categories': [{'measurements': [{'value': '186', 'groupId': 'OG000'}, {'value': '190', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '0-24 hours', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Percentage of Patients With no Emetic Episodes in the Delayed Phase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '225', 'groupId': 'OG000'}, {'value': '215', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'I.V. Palonosetron Infusion Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}, {'id': 'OG001', 'title': 'I.V. Palonosetron Bolus Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}], 'classes': [{'categories': [{'measurements': [{'value': '176', 'groupId': 'OG000'}, {'value': '168', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '>24-120 hours', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Percentage of Patients With no Emetic Episodes in the Overall Phase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '225', 'groupId': 'OG000'}, {'value': '215', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'I.V. Palonosetron Infusion Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}, {'id': 'OG001', 'title': 'I.V. Palonosetron Bolus Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}], 'classes': [{'categories': [{'measurements': [{'value': '155', 'groupId': 'OG000'}, {'value': '160', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '0-120 hours', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Percentage of Patients With no Rescue Medication in the Acute Phase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '225', 'groupId': 'OG000'}, {'value': '215', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'I.V. Palonosetron Infusion Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}, {'id': 'OG001', 'title': 'I.V. Palonosetron Bolus Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}], 'classes': [{'categories': [{'measurements': [{'value': '200', 'groupId': 'OG000'}, {'value': '195', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '0-24 hours', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Percentage of Patients With no Rescue Medication in the Delayed Phase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '225', 'groupId': 'OG000'}, {'value': '215', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'I.V. Palonosetron Infusion Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}, {'id': 'OG001', 'title': 'I.V. Palonosetron Bolus Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}], 'classes': [{'categories': [{'measurements': [{'value': '183', 'groupId': 'OG000'}, {'value': '176', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '>24-120 hours', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Percentage of Patients With no Rescue Medication in the Overall Phase', 'denoms': [{'units': 'Participants', 'counts': [{'value': '225', 'groupId': 'OG000'}, {'value': '215', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'I.V. Palonosetron Infusion Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}, {'id': 'OG001', 'title': 'I.V. Palonosetron Bolus Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}], 'classes': [{'categories': [{'measurements': [{'value': '173', 'groupId': 'OG000'}, {'value': '169', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '0-120 hours', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'I.V. Palonosetron Infusion Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}, {'id': 'FG001', 'title': 'I.V. Palonosetron Bolus Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '225'}, {'groupId': 'FG001', 'numSubjects': '215'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '218'}, {'groupId': 'FG001', 'numSubjects': '206'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '7'}, {'groupId': 'FG001', 'numSubjects': '9'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '225', 'groupId': 'BG000'}, {'value': '215', 'groupId': 'BG001'}, {'value': '440', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'I.V. Palonosetron Infusion Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}, {'id': 'BG001', 'title': 'I.V. Palonosetron Bolus Plus Dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.\n\nPalonosetron\n\nDexamethasone'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '59.9', 'spread': '8.7', 'groupId': 'BG000'}, {'value': '58.9', 'spread': '8.5', 'groupId': 'BG001'}, {'value': '59.4', 'spread': '8.6', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '74', 'groupId': 'BG000'}, {'value': '71', 'groupId': 'BG001'}, {'value': '145', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '151', 'groupId': 'BG000'}, {'value': '144', 'groupId': 'BG001'}, {'value': '295', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '225', 'groupId': 'BG000'}, {'value': '215', 'groupId': 'BG001'}, {'value': '440', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'ECOG Performance Status', 'classes': [{'categories': [{'title': 'Grade 0', 'measurements': [{'value': '97', 'groupId': 'BG000'}, {'value': '109', 'groupId': 'BG001'}, {'value': '206', 'groupId': 'BG002'}]}, {'title': 'Grade 1', 'measurements': [{'value': '120', 'groupId': 'BG000'}, {'value': '100', 'groupId': 'BG001'}, {'value': '220', 'groupId': 'BG002'}]}, {'title': 'Grade 2', 'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '14', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': "The ECOG Scale is a standard criteria for measuring how the cancer disease impacts a patient's daily living abilities (known to physicians and researchers as a patient's performance status). It describes a patient's level of functioning in terms of their ability to care for themself, daily activity, and physical ability (walking, working, etc.). There 6 grades, where the performance gets worsening from 0 (patient is fully active, able to carry on all pre-disease performance without restriction) to 5 (patient is dead).", 'unitOfMeasure': 'Participants'}, {'title': 'Alcohol consumption', 'classes': [{'categories': [{'title': 'None', 'measurements': [{'value': '160', 'groupId': 'BG000'}, {'value': '145', 'groupId': 'BG001'}, {'value': '305', 'groupId': 'BG002'}]}, {'title': 'Occasional', 'measurements': [{'value': '58', 'groupId': 'BG000'}, {'value': '67', 'groupId': 'BG001'}, {'value': '125', 'groupId': 'BG002'}]}, {'title': 'Regular', 'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '10', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Tobacco consumption', 'classes': [{'categories': [{'title': 'non-smoker', 'measurements': [{'value': '81', 'groupId': 'BG000'}, {'value': '77', 'groupId': 'BG001'}, {'value': '158', 'groupId': 'BG002'}]}, {'title': 'Ex-smoker', 'measurements': [{'value': '81', 'groupId': 'BG000'}, {'value': '70', 'groupId': 'BG001'}, {'value': '151', 'groupId': 'BG002'}]}, {'title': 'Regular', 'measurements': [{'value': '60', 'groupId': 'BG000'}, {'value': '66', 'groupId': 'BG001'}, {'value': '126', 'groupId': 'BG002'}]}, {'title': 'Occasional', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '5', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 441}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2015-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-06', 'dispFirstSubmitDate': '2016-03-23', 'completionDateStruct': {'date': '2016-03', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-06-18', 'studyFirstSubmitDate': '2015-09-21', 'dispFirstSubmitQcDate': '2016-03-23', 'resultsFirstSubmitDate': '2018-05-09', 'studyFirstSubmitQcDate': '2015-09-21', 'dispFirstPostDateStruct': {'date': '2016-04-26', 'type': 'ESTIMATED'}, 'lastUpdatePostDateStruct': {'date': '2018-06-20', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2018-06-18', 'studyFirstPostDateStruct': {'date': '2015-09-22', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2018-06-20', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2016-03', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Acute Phase', 'timeFrame': '0-24 hours'}], 'secondaryOutcomes': [{'measure': 'Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Delayed Phase', 'timeFrame': '>24-120 hours'}, {'measure': 'Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, in the Overall Phase', 'timeFrame': '0-120 hours'}, {'measure': 'Percentage of Patients With no Emetic Episodes in the Acute Phase', 'timeFrame': '0-24 hours'}, {'measure': 'Percentage of Patients With no Emetic Episodes in the Delayed Phase', 'timeFrame': '>24-120 hours'}, {'measure': 'Percentage of Patients With no Emetic Episodes in the Overall Phase', 'timeFrame': '0-120 hours'}, {'measure': 'Percentage of Patients With no Rescue Medication in the Acute Phase', 'timeFrame': '0-24 hours'}, {'measure': 'Percentage of Patients With no Rescue Medication in the Delayed Phase', 'timeFrame': '>24-120 hours'}, {'measure': 'Percentage of Patients With no Rescue Medication in the Overall Phase', 'timeFrame': '0-120 hours'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Chemotherapy-Induced Nausea and Vomiting']}, 'descriptionModule': {'briefSummary': 'PALO-15-17 is a clinical study assessing efficacy and safety of a single dose of palonosetron 0.25 mg administered as a 30-minute IV infusion compared to palonosetron 0.25 mg administered as a 30-second IV bolus (Aloxi, an antiemetic drug), both given with oral dexamethasone. The objective of the study is to demonstrate that infused IV palonosetron 0.25 mg is as effective as (non-inferior to) injected palonosetron IV 0.25 mg to prevent nausea and vomiting induced by highly emetogenic cancer chemotherapy in the 0-24 hours after administration of a single cycle of highly emetogenic chemotherapy'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Signed written informed consent\n* Histologically or cytologically confirmed solid tumor malignancy.\n* Naïve to cytotoxic chemotherapy. Previous biological or hormonal therapy will be permitted.\n* Scheduled to receive first course of one of the following reference HEC, alone or in combination with other chemotherapeutic agents on Day 1:\n\n * cisplatin administered as a single IV dose of ≥ 70 mg/m2\n * cyclophosphamide ≥1500 mg/m2\n * carmustine (BCNU) \\>250 mg/m2\n * dacarbazine (DTIC)\n * mechloretamine (nitrogen mustard)\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 .\n* If a patient is female, she shall be of non-childbearing potential or of childbearing potential using reliable contraceptive measures and having a negative urine pregnancy test.\n* Hematologic and metabolic status adequate for receiving an highly emetogenic regimen based on laboratory criteria (Total Neutrophils,Platelets, Bilirubin, Liver enzymes, Serum Creatinine or Creatinine Clearance)\n* Able to read, understand, follow the study procedure and complete patient diary.\n\nExclusion Criteria:\n\n* Lactating woman.\n* Current use of illicit drugs or current evidence of alcohol abuse.\n* Scheduled to receive moderately emetogenic chemotherapy or highly emetogenic chemotherapy from Day 2 to Day 5.\n* Received or is scheduled to receive radiation therapy to the abdomen or the pelvis within 1 week prior to the start of the reference HEC administration on Day 1 or between Days 1 to 5.\n* Any vomiting, retching, or nausea (grade ≥ 1 as defined by National Cancer Institute) within 24 hours prior to the start of the reference HEC administration on Day 1.\n* Symptomatic primary or metastatic CNS malignancy.\n* Active peptic ulcer disease, gastrointestinal obstruction, increased intracranial pressure, hypercalcemia, an active infection or any illness or medical conditions (other than malignancy) that, in the opinion of the Investigator, may confound the results of the study, represent another potential etiology for emesis and nausea (other than chemotherapy-induced nausea and vomiting) or pose unwarranted risks in administering the study drugs to the patient.\n* Known hypersensitivity or contraindication to 5-HT3 receptor antagonists\n* Known contraindication to the IV administration of 50 mL 5% glucose solution.\n* Participation in a previous clinical trial involving palonosetron.\n* Any investigational drugs (other than those given in this study) taken within 4 weeks prior to Day 1, and/or is scheduled to receive any investigational drug during the present study.\n* Systemic corticosteroid therapy at any dose within 72 hours prior to the start of the reference HEC administration on Day 1. However, topical and inhaled corticosteroids are permitted.\n* Scheduled to receive bone marrow transplantation and/or stem cell rescue therapy.\n* Any medication with known or potential antiemetic activity within 24 hours prior to the start of the reference HEC administration on Day 1, including but not limited to 5-HT3 receptor antagonists and NK-1 receptor antagonists\n* Concurrent medical condition that would preclude administration of dexamethasone for 4 days such as systemic fungal infection or uncontrolled diabetes.'}, 'identificationModule': {'nctId': 'NCT02557035', 'briefTitle': 'An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting', 'organization': {'class': 'INDUSTRY', 'fullName': 'Helsinn Healthcare SA'}, 'officialTitle': 'A Phase 3, Single-dose, Multicenter, Randomized, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of Palonosetron 0.25 mg Administered as a 30-minute IV Infusion Compared to Palonosetron 0.25 mg Administered as a 30-second IV Bolus for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy.', 'orgStudyIdInfo': {'id': 'PALO-15-17'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'I.V. palonosetron infusion plus dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.', 'interventionNames': ['Drug: Palonosetron', 'Drug: Dexamethasone']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'I.V. palonosetron bolus plus dexamethasone', 'description': 'Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.', 'interventionNames': ['Drug: Palonosetron', 'Drug: Dexamethasone']}], 'interventions': [{'name': 'Palonosetron', 'type': 'DRUG', 'armGroupLabels': ['I.V. palonosetron bolus plus dexamethasone', 'I.V. palonosetron infusion plus dexamethasone']}, {'name': 'Dexamethasone', 'type': 'DRUG', 'armGroupLabels': ['I.V. palonosetron bolus plus dexamethasone', 'I.V. palonosetron infusion plus dexamethasone']}]}, 'contactsLocationsModule': {'locations': [{'zip': '223052', 'city': 'Lesnoy', 'country': 'Belarus', 'facility': 'N.N. Aleksandrov Republican Research Oncology and Medical Radiology Center, Department of Chemotherapy', 'geoPoint': {'lat': 51.8625, 'lon': 26.7547}}, {'zip': '220013', 'city': 'Minsk', 'country': 'Belarus', 'facility': 'Minsk City Clinical Oncology Center', 'geoPoint': {'lat': 53.90019, 'lon': 27.56653}}, {'city': 'Banja Luka', 'country': 'Bosnia and Herzegovina', 'facility': 'University Clinical Centre of the Republic of Srpska', 'geoPoint': {'lat': 44.77879, 'lon': 17.20629}}, {'zip': '9300', 'city': 'Dobrich', 'country': 'Bulgaria', 'facility': 'Multiprofile Hospital for Active Treatment, Dobrich, Department of Medical Oncology', 'geoPoint': {'lat': 43.56491, 'lon': 27.83138}}, {'zip': '6300', 'city': 'Haskovo', 'country': 'Bulgaria', 'facility': 'Specialized Hospital for Active Treatment in Oncology, Haskovo, Department of Medical Oncology', 'geoPoint': {'lat': 41.93415, 'lon': 25.55557}}, {'zip': '4002', 'city': 'Plovdiv', 'country': 'Bulgaria', 'facility': 'Multiprofile Hospital for Active Treatment "Central Onco Hospital", Plovdiv, Department of Medical Oncology', 'geoPoint': {'lat': 42.15387, 'lon': 24.75001}}, {'zip': '7002', 'city': 'Rousse', 'country': 'Bulgaria', 'facility': 'Complex Oncology Center, Ruse, Department of Medical Oncology', 'geoPoint': {'lat': 43.84872, 'lon': 25.9534}}, {'zip': '1303', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Multiprofile Hospital for Active Treatment "Serdika", Sofia, Department of Medical Oncology', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1431', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'University Multiprofile Hospital for Active Treatment "Sveti Ivan Rilski", Sofia, Department of Medical Oncology', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Multiprofile Hospital for Active Treatment for Wonen\'s Health "Nadezhda"', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '9010', 'city': 'Varna', 'country': 'Bulgaria', 'facility': 'Hospital for Active Treatment of Oncological Diseases "Dr. Marko Antonov Markov", Varna, Department of Medicinal Oncology and Palliative Care', 'geoPoint': {'lat': 43.21912, 'lon': 27.91024}}, {'zip': '9010', 'city': 'Varna', 'country': 'Bulgaria', 'facility': 'Multiprofile Hospital for Active Treatment "Sveta Marina", Varna, Clinic of Medical Oncology', 'geoPoint': {'lat': 43.21912, 'lon': 27.91024}}, {'zip': '0131', 'city': 'Tbilisi', 'country': 'Georgia', 'facility': 'JSC NeoMedi', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}, {'zip': '0159', 'city': 'Tbilisi', 'country': 'Georgia', 'facility': 'LTD Institute of Clinical Oncology', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}, {'zip': '0160', 'city': 'Tbilisi', 'country': 'Georgia', 'facility': 'LTD Aversi Clinic', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}, {'city': 'Tbilisi', 'country': 'Georgia', 'facility': 'LDT High Technology Medical Center University Clinic', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}, {'city': 'Athens', 'country': 'Greece', 'facility': '"Sotiria" Chest Diseases Hospital of Athens', 'geoPoint': {'lat': 37.98376, 'lon': 23.72784}}, {'zip': '570 01', 'city': 'Thessaloniki', 'country': 'Greece', 'facility': 'Thermi Clinic S.A.', 'geoPoint': {'lat': 40.64072, 'lon': 22.93493}}, {'zip': '570 10', 'city': 'Thessaloniki', 'country': 'Greece', 'facility': 'General Hospital of Thessaloniki "G. Papanikolaou", University Department of Pulmonology', 'geoPoint': {'lat': 40.64072, 'lon': 22.93493}}, {'city': 'Thessaloniki', 'country': 'Greece', 'facility': 'Bioclinic Thessalonikis S.A.', 'geoPoint': {'lat': 40.64072, 'lon': 22.93493}}, {'zip': '1121', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Koranyi National Institute of TBC and Pulmonology', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '1145', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Uzsoki Hospital, Department of Radiation Oncology', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'city': 'Debrecen', 'country': 'Hungary', 'facility': 'University of Debrecen, Medical and Health Science Center', 'geoPoint': {'lat': 47.53167, 'lon': 21.62444}}, {'zip': '9024', 'city': 'Győr', 'country': 'Hungary', 'facility': 'Petz Aladar County Teaching Hospital, Center for Oncoradiology', 'geoPoint': {'lat': 47.68333, 'lon': 17.63512}}, {'zip': '7400', 'city': 'Kaposvár', 'country': 'Hungary', 'facility': 'Kaposi Mor Teaching Hospital, Centre for Clinical Oncology', 'geoPoint': {'lat': 46.36667, 'lon': 17.8}}, {'zip': '3526', 'city': 'Miskolc', 'country': 'Hungary', 'facility': 'Borsod-Abauj-Zemplen County Hospital and University Educational Hospital', 'geoPoint': {'lat': 48.10327, 'lon': 20.77806}}, {'city': 'Nyíregyháza', 'country': 'Hungary', 'facility': 'Szabolcs-Szatmar-Bereg County Hospitals and University Teaching Hospital', 'geoPoint': {'lat': 47.95539, 'lon': 21.71671}}, {'city': 'Pécs', 'country': 'Hungary', 'facility': 'Medical Center of the University of Pecs', 'geoPoint': {'lat': 46.07617, 'lon': 18.22814}}, {'zip': '45434', 'city': 'Kaunas', 'country': 'Lithuania', 'facility': 'Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Oncology Hospital, Department of Conservative Oncology', 'geoPoint': {'lat': 54.90156, 'lon': 23.90909}}, {'zip': '50009', 'city': 'Kaunas', 'country': 'Lithuania', 'facility': 'Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Clinic of Oncology and Hematology', 'geoPoint': {'lat': 54.90156, 'lon': 23.90909}}, {'city': 'Baia Mare', 'country': 'Romania', 'facility': 'Oncopremium Team SRL, Department of Oncology', 'geoPoint': {'lat': 47.65729, 'lon': 23.56808}}, {'zip': '022328', 'city': 'Bucharest', 'country': 'Romania', 'facility': 'Prof. Dr. Alexandru Trestioreanu Institute of Oncology, Medical Oncology Department II', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'zip': '030171', 'city': 'Bucharest', 'country': 'Romania', 'facility': 'Coltea Clinical Hospital, Department of Medical Oncology', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'zip': '031864', 'city': 'Bucharest', 'country': 'Romania', 'facility': 'Hifu Terramed Conformal SRL, Department of Medical Oncology', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'city': 'Bucharest', 'country': 'Romania', 'facility': 'Ianuli Med Consult SRL, Oncology Department', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'zip': '400015', 'city': 'Cluj-Napoca', 'country': 'Romania', 'facility': '"Prof. Dr. Ion Chiricuta" Institute of Oncology, Radiotherapy Department I', 'geoPoint': {'lat': 46.76667, 'lon': 23.6}}, {'city': 'Cluj-Napoca', 'country': 'Romania', 'facility': 'Radiotherapy Center Cluj SRL, Department of Oncology', 'geoPoint': {'lat': 46.76667, 'lon': 23.6}}, {'zip': '900591', 'city': 'Constanța', 'country': 'Romania', 'facility': 'Constanta Emergency Clinical County Hospital, Department of Medical Oncology', 'geoPoint': {'lat': 44.18073, 'lon': 28.63432}}, {'city': 'Craiova', 'country': 'Romania', 'facility': 'Oncology Center "Sf. Nectarie", Department of Medical Oncology', 'geoPoint': {'lat': 44.31667, 'lon': 23.8}}, {'zip': '720237', 'city': 'Suceava', 'country': 'Romania', 'facility': 'Suceava Sf. Ioan cel Nou Emergency County Hospital, Department of Medical Oncology', 'geoPoint': {'lat': 47.63333, 'lon': 26.25}}, {'zip': '300239', 'city': 'Timișoara', 'country': 'Romania', 'facility': 'Oncomed SRL, Department of Medical Oncology', 'geoPoint': {'lat': 45.75372, 'lon': 21.22571}}, {'city': 'Timișoara', 'country': 'Romania', 'facility': 'Oncocenter Clinical Oncology SRL, Department of Medical Oncology', 'geoPoint': {'lat': 45.75372, 'lon': 21.22571}}, {'city': 'Arkhangelsk', 'country': 'Russia', 'facility': 'Arkhangelsk Clinical Oncology Center', 'geoPoint': {'lat': 64.5461, 'lon': 40.55183}}, {'city': 'Barnaul', 'country': 'Russia', 'facility': 'Altay Territorial Oncology Center', 'geoPoint': {'lat': 53.36199, 'lon': 83.72786}}, {'city': 'Bryansk', 'country': 'Russia', 'facility': 'Bryansk Regional Oncology Center', 'geoPoint': {'lat': 53.27096, 'lon': 34.32143}}, {'city': 'Chelyabinsk', 'country': 'Russia', 'facility': 'Chelyabinsk Regional Clinical Oncology Center', 'geoPoint': {'lat': 55.1611, 'lon': 61.42877}}, {'city': 'Chelyabinsk', 'country': 'Russia', 'facility': 'Evimed, LLC', 'geoPoint': {'lat': 55.1611, 'lon': 61.42877}}, {'city': 'Ivanovo', 'country': 'Russia', 'facility': 'Ivanovo Regional Oncology Center', 'geoPoint': {'lat': 56.99988, 'lon': 40.97257}}, {'city': 'Kaluga', 'country': 'Russia', 'facility': 'Kaluga Regional Oncology Center', 'geoPoint': {'lat': 54.53063, 'lon': 36.27}}, {'city': "Kazan'", 'country': 'Russia', 'facility': 'Republican Clinical Oncology Center', 'geoPoint': {'lat': 55.78874, 'lon': 49.12214}}, {'city': 'Krasnoyarsk', 'country': 'Russia', 'facility': 'Krasnoyarsk A.I. Kryzhanovsky Regional Oncology Center', 'geoPoint': {'lat': 56.03742, 'lon': 92.93136}}, {'city': 'Moscow', 'country': 'Russia', 'facility': 'Moscow City Oncology Hospital #62', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'city': 'Moscow', 'country': 'Russia', 'facility': 'Moscow Clinical Scientific and Practical Center', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'city': 'Moscow', 'country': 'Russia', 'facility': 'N.N. Blokhin Russian Oncology Research Center, Surgery Dept. 2', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'city': 'Moscow', 'country': 'Russia', 'facility': 'N.N. Blokhin Russian Oncology Research Center, Surgery Dept. of Female Reproductive System Tumors', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'city': 'Moscow', 'country': 'Russia', 'facility': 'N.N. Blokhin Russian Oncology Research Center', 'geoPoint': {'lat': 55.75204, 'lon': 37.61781}}, {'city': 'Nizhny Novgorod', 'country': 'Russia', 'facility': 'Branch #1 of Nizhny Novgorod Regional Oncology Center', 'geoPoint': {'lat': 56.32867, 'lon': 44.00205}}, {'city': 'Novosibirsk', 'country': 'Russia', 'facility': 'City Clinical Hospital #1', 'geoPoint': {'lat': 55.02259, 'lon': 82.93175}}, {'city': 'Novosibirsk', 'country': 'Russia', 'facility': 'Novosibirsk Regional Oncology Center', 'geoPoint': {'lat': 55.02259, 'lon': 82.93175}}, {'city': 'Omsk', 'country': 'Russia', 'facility': 'Clinical Oncology Center, Dept. of Chemotherapy', 'geoPoint': {'lat': 54.99244, 'lon': 73.36859}}, {'city': 'Omsk', 'country': 'Russia', 'facility': 'Clinical Oncology Center', 'geoPoint': {'lat': 54.99244, 'lon': 73.36859}}, {'city': 'Orenburg', 'country': 'Russia', 'facility': 'Orenburg Regional Clinical Oncology Center', 'geoPoint': {'lat': 51.76712, 'lon': 55.09883}}, {'city': 'Pyatigorsk', 'country': 'Russia', 'facility': 'Pyatigorsk Oncology Center', 'geoPoint': {'lat': 44.05, 'lon': 43.05036}}, {'city': 'Ryazan', 'country': 'Russia', 'facility': 'Regional Clinical Oncology Center', 'geoPoint': {'lat': 54.62696, 'lon': 39.70415}}, {'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'City Clinical Oncology Center, Thoracic Oncology Dept.', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'City Clinical Oncology Center, Urology Oncology Dept.', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'City Clinical Oncology Center', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'First I.P. Pavlov State Medical University of St. Petersburg', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'city': 'Saint Petersburg', 'country': 'Russia', 'facility': 'St.Petersburg Municipal Clinical Oncology Center', 'geoPoint': {'lat': 59.93863, 'lon': 30.31413}}, {'city': 'Samara', 'country': 'Russia', 'facility': 'Samara Regional Clinical Oncology Center', 'geoPoint': {'lat': 53.20767, 'lon': 50.13553}}, {'city': 'Tambov', 'country': 'Russia', 'facility': 'Tambov Regional Oncology Center', 'geoPoint': {'lat': 52.73632, 'lon': 41.44102}}, {'city': 'Tomsk', 'country': 'Russia', 'facility': 'Tomsk Research Institute of Oncology, General Oncology Dept.', 'geoPoint': {'lat': 56.50049, 'lon': 84.98216}}, {'city': 'Tomsk', 'country': 'Russia', 'facility': 'Tomsk Research Institute of Oncology', 'geoPoint': {'lat': 56.50049, 'lon': 84.98216}}, {'city': 'Ufa', 'country': 'Russia', 'facility': 'Republican Clinical Oncology Center', 'geoPoint': {'lat': 54.74306, 'lon': 55.96779}}, {'city': 'Veliky Novgorod', 'country': 'Russia', 'facility': 'Regional Clinical Oncology Center', 'geoPoint': {'lat': 58.52131, 'lon': 31.27104}}, {'city': 'Yekaterinburg', 'country': 'Russia', 'facility': 'Sverdlovsk Regional Oncology Center', 'geoPoint': {'lat': 56.85733, 'lon': 60.61529}}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Helsinn Healthcare SA', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'PSI CRO', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}